ERNAW
Ernexa Therapeutics Inc.
NASDAQ · Financial Services · Asset Management · US
$0.03
+0.64%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$0.04
From 52W high−82.49%
Volume6300.00
Market cap$247372.40
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$0.04
From 52W high
−82.49%
Volume
6300.00
Market cap
$247372.40
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.9x
P/E (TTM)
—
RSI (14)
42.0
MomentumView details →
1D Return
+0.64%
YTD Return
—
SummaryUpdated Jun 1, 2026
Eterna Therapeutics Inc. (NASDAQ:ERNA), formerly known as Brooklyn ImmunoTherapeutics, is a clinical-stage biopharmaceutical company founded in 1991 and based in Brooklyn, New York. The company focuses on developing innovative cancer treatments through immunotherapy and advanced gene-editing technologies. As a biotechnology firm in the oncology space, Eterna operates in the high-risk, high-reward pharmaceutical development sector where companies invest years and substantial capital to bring potentially life-saving treatments from laboratory research through clinical trials to market approval.
Similar companies
Latest newsMore news →
Ernexa Therapeutics Inc. appointed Robert J. Spiegel, M.D. to its Board of Directors effective September 14, 2026.4d agoErnexa Therapeutics reported positive preclinical disease-modifying data for ERNA-201 in the collagen-induced arthritis model, supporting its engineered synthetic iMSC platform.5d ago